• Assess the cost-effectiveness of sitagliptin versus sulfonylurea as an add-on therapy to metformin among type 2 diabetes patients currently on metformin but not achieving HbA1c goal in Belgium
• The impact of treatments on risk factors and side effects was based on clinical trials, observational studies, systematic reviews and meta-analyses of relevant RCTs, as well as the most recent findings on the potential benefit of DPP4 on other-cause mortality and cardiovascular diseases and the possible detrimental effect of sulfonylurea on myocardial infarction (MI)
• European patient profiles and Belgium-specific data on drug prices, diabetesrelated complication treatment costs, treatment patterns and guidelines were used JANUVIA ® (sitagliptan) Diabetes Economic (JADE) model • An individual level simulation model to project the long term impacts of alternative treatment strategies on health outcomes, costs, and cost-effectiveness for T2DM patients
• Incorporating an integrated set of risk equations/algorithm from the UKPDS Outcomes Model 2 and extending it by allowing a treatment strategy comprising a series of treatment regimens 
Inputs and Assumptions
• A payer's perspective
• Only direct costs were included
• Simulation cycle was every 6 months (ie, patient profile, treatment, risk factors, side effects, costs, and health status were updated every 6 months)
• Lifetime horizon was 50 years, with upper age limit of 99 years
• Costs and effects were discounted at 3% and 1.5% annually 
Efficacy and Safety Inputs and Assumptions
• Efficacy and safety data for those patients continuing sitagliptin or SU treatment without discontinuation primarily came from Merck conducted head-to-head trial PN024 3 (per protocol patients defined at Week 52)
• PN024 was a 52 week, multinational, randomised, parallel-group, non-inferiority trial evaluating the efficacy and safety of once daily sitagliptin vs SU given on a background of metformin (≥1500 mg/day)
• Insulin data, both once-daily basal insulin and multiple daily insulin, are obtained from 4-T trial (Holman, et • Recent findings showed that DPP-4 may have benefit on other-cause mortality and cardiovascular diseases [6] [7] [8] [9] [10] , and that may be associated with increased risks of mortality and sulphonylurea-induced cardiovascular events [11] [12] [13] [14] • Based on the recent finding, on top of the risk projected by UKPDS risk equations for each treatment, sitagliptin was assumed to have a 10% risk reduction of MI and a 15% risk reduction of other-cause mortality compared to SU
• The relative risk reductions for sitagliptin assumed were lower than the numbers suggested in the studies reviewed above. • No additional relative risk reductions for sitagliptin were assumed on stroke or CV mortality, even though such reductions were suggested in some of the studies reviewed
Results
• Over the lifetime horizon, MF+Sita strategy was projected to cost Euro 1,102 more than MF+SU strategy per patient, with the majority excess costs coming from prescription drug costs
• The life expectancy was 0.077 years greater per patient with MF+Sita strategy than with MF+SU strategy. The estimated discounted incremental QALY was 0.082 years, favoring MF+Sita strategy due to better hypoglycemia, weight, and MI risk profile
• The estimated ICER for the base case was Euro 13,460 per Qaly gained (discounted costs/ discounted Qaly). The estimated ICER indicated sitagliptin strategy would be cost effective comparing to sulfonylurea strategy even at a CE threshold of Euro 15,000 per QALY gained 
